Stock comparison
AstraZeneca PLC is 257.9x more valuable than Jade Biosciences, Inc. by market capitalization ($286.27 B vs $1.11 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
AZN is larger
AstraZeneca PLC is 257.9x more valuable than Jade Biosciences, Inc. by market capitalization ($286.27 B vs $1.11 B).
Market value leader
AZN
AstraZeneca PLC is 257.9x more valuable than Jade Biosciences, Inc. by market capitalization ($286.27 B vs $1.11 B).
| Metric | JBIO | AZN |
|---|---|---|
| Market cap | $1.11 B | $286.27 B |
| US-listed rank | #2576 | #50 |
| Net income (latest FY) | -$127.41M | - |
| Net margin | - | - |
| P/E (trailing FY) | - | - |
| SEC filings | 477 | 1,004 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
AstraZeneca PLC is 257.9x more valuable than Jade Biosciences, Inc. by market capitalization ($286.27 B vs $1.11 B).
Full pages: Jade Biosciences, Inc. and AstraZeneca PLC, or browse the full rankings.